Slate Path Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Slate Path Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-145,000	Closed	-$2.94M	–	31
2017 Q3	$2.94M	Buy	+145,000	New	+$2.77M	0.15%	23
2015 Q4	–	Sell	-735,000	Closed	-$25.9M	–	16
2015 Q3	$25.9M	Sell	735,000 -1,100,000	-60%	-$49.6M	2.97%	10
2015 Q2	$84.3M	Sell	1,835,000 -100,000	-5%	-$4.75M	9.2%	7
2015 Q1	$90.7M	Sell	1,935,000 -395,000	-17%	-$15.7M	5.72%	8
2014 Q4	$73.8M	Hold	2,330,000	–	–	5.16%	10
2014 Q3	$55.2M	Buy	+2,330,000	New	+$59.7M	2.48%	15

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Slate Path Capital's IPXL Position: Q4 2017 in Review

Slate Path Capital sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 145,000 shares — an estimated $2.94M sold.

Slate Path Capital first reported a position in IPXL in Q3 2014 and held it in 6 quarters. The position peaked at $90.7M in Q1 2015. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

Slate Path Capital reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
Slate Path Capital sold 145,000 Impax Laboratories, Inc. shares in Q4 2017, an estimated $2.94M.
Slate Path Capital first reported a position in Impax Laboratories, Inc. in Q3 2014 and held it in 6 quarters.
Slate Path Capital's Impax Laboratories, Inc. position peaked at $90.7M in Q1 2015.
200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Slate Path Capital's 13F filing for Q4 2017, filed 14 Feb 2018.